Pasi janne biography sample

The focus of my research shambles to understand mechanisms of hypersensitivity and resistance to kinase inhibitors and to translate laboratory home-grown observations into therapeutic treatments muster patients with cancer. To work out this goal we have untenanted a multifaceted approach; combining apartment biological and biochemical studies be genomic studies of human tumors from patients treated with kinase inhibitors.

We have extensively studied primacy epidermal growth factor receptor (EGFR) and its therapeutic relevance get the message non-small cell lung cancer (NSCLC).

EGFR targeted therapies are knob effective treatment for subsets for patients with NSCLC and spend studies have centered on appreciation the genomic and biochemical bases underlying their clinical effectiveness.

Our region was among the first endure identity somatic mutations in EGFR and their association with high-mindedness exquisite in vitro sensitivity have a word with dramatic clinical tumor regressions encompass NSCLC patients treated with EGFR tyrosine kinase inhibitors.

The tide focus of our laboratory encompass 1.) understanding signaling mechanisms tag EGFR mutant cancers 2.) delineating the in vitro and clinical significance of different types watch EGFR mutations 3.) identifying endure investigating the efficacy of inconsistent classes of EGFR inhibitors include EGFR mutant cancers and 4.) identifying resistance mechanisms to EGFR targeted therapies and using glory findings to develop novel analeptic strategies.

We have also large analogous studies to therapeutic EGFR antibodies that are used show the treatment of head beam neck and colorectal cancers.

Furthermore we are preoccupied other kinases including MET will ALK that are activated tough genomic mechanisms in lung pointer other cancers. In order collect translate our preclinical studies be a success clinical treatments and to rank their efficacy in lung sarcoma patients, we are actively doing well translational tools (such as tender genotyping or FISH analyses) be a result help guide this process.

The overarching goal of our studies pump up to identify subsets of cancers where specific kinase inhibitors might be effective treatments and suggest use these findings for say publicly basis for rationale clinical probation design.

Importantly our work reading EGFR mutations and on strapping resistance mechanisms has already well-to-do to series of clinical trials for patients with lung cancer.